Sarepta Drops After U.K. Trial Halt, But Analysts Unconcerned
February 09, 2018 at 13:50 PM EST
Shares of Sarepta Therapeutics dropped in morning trading following a report that said that the company had halted treatment at sites in the United Kingdom testing its Duchenne muscular dystrophy drug golodirsen.